Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,206,861 papers from all fields of science
Search
Sign In
Create Free Account
Mimpara
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
cinacalcet
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
The Beneficial Effect of Paricalcitol (Zemplar) on Secondary hyperparathyroidism Refractory to Calcitriol (Calcijex) and Cinacalcet HCl (Mimpara) in Patients on Maintenance Hemodialysis: A…
K. El-Reshaid
,
Shaikha Al-Bader
,
Salah El-Marzabani
2020
Corpus ID: 219634438
Paricalcitol, 19-nor-1, 25-dihydroxvitamin D2, is a novel 1,25–dihydroxyvitamin D2 analogue, which has greater potential to…
Expand
2017
2017
Avaluació de l’efectivitat i la seguretat del cinacalcet en pacients amb malaltia renal crònica i hiperparatiroïdisme secundari sense tractament renal substitutiu
Ariadna Pérez Ricart
2017
Corpus ID: 79555979
Introduccio: L’hiperparatiroidisme secundari (HPTS) es una complicacio frequent de la malaltia renal cronica (MRC), caracteritzat…
Expand
2015
2015
PHARMACOECONOMIC EVALUATION OF TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS ON DIALYSIS WITH CINACALCET
R. Yagudina
,
V. Serpik
2015
Corpus ID: 218084718
Abstract: the pharmacoeconomic study compared the standard drug therapy (vitamin D and phosphorbinders) of secondary…
Expand
2014
2014
Calcimimetic (Cinacalcet) and Hemodiafiltration Versus Conventional Treatment of Secondary Hyperparathyroidism in Children with End-Stage Renal Disease on Regular Hemodialysis
F. Fadel
,
S. Sabry
,
M. Farouk
,
R. Essam
,
M. Ghoneim
,
A. Ismael
2014
Corpus ID: 73799347
Background Control of metabolic derangements related to bone disease is one of the important goals in management of patients with…
Expand
2012
2012
Фармакоэкономическая оценка лечения вторичного гиперпаратиреоза у пациентов, находящихся на системном диализе, лекарственным средством цинакалцет
В. Г. Серпик
2012
Corpus ID: 74974356
Abstract: the pharmacoeconomic study compared the standard drug therapy (vitamin D and phosphorbinders) of secondary…
Expand
2011
2011
[The assessment of cynacalcet (Mimpara) accompanied by alfacalcidol treatment efficacy in haemodialysis patients with different secondary hyperparathyroidism severity recognized by iPTH].
R. Zwiech
,
P. Dryja
,
+5 authors
S. Chrul
Wiadomosci lekarskie
2011
Corpus ID: 12134799
INTRODUCTION Calcimimetics are highly efficient drugs in treatment of secondary hyperparathyroidism (sHPT) in patients on…
Expand
2010
2010
PUK5 ECONOMIC EVALUATION OF EVEROLIMUS WITH REDUCED-DOSE CYCLOSPORINE IN DE NOVO RENAL TRANSPLANT RECIPIENTS IN HUNGARY
A. Palmer
,
B. Standaert
,
Van Kriekinge
2010
Corpus ID: 165158705
PUK3 CLINICAL IMPACT OF NONCOMPLIANCE AFTER RENAL TRANSPLANTATION Babarykin D, Folkmane I,Adamsone I, Bicans J, Rozental R…
Expand
2009
2009
[Cinacalcet in the treatment of secondary hyperparathyreoidism in a child with chronic kidney disease--case report].
D. Runowski
,
B. Jachimiak
Polski merkuriusz lekarski : organ Polskiego…
2009
Corpus ID: 9933229
UNLABELLED The medical history and treatment of 2.5 years old girl with chronic kidney disease and heavy hyperparathyreoidism was…
Expand
2007
2007
Actuación de enfermería relacionada con pacientes en diálisis peritoneal y tratamiento con Cinacalcet
Almudena Ortigosa Barriola
,
C. Ramos
,
Mª Pilar González
,
J. P. Pérez
2007
Corpus ID: 170434328
El hiperparatiroidismo secundario a IRCT es una complicacion frecuente y se asocia a un elevado indice de morbilidad en pacientes…
Expand
2006
2006
Hyperkalzämie bei dialysepflichtiger Niereninsuffizienz
Hyperkalzämie bei dialyse
,
pflichtiger Niereninsuffizienz
Der Internist
2006
Corpus ID: 34729502
Die Autoren berichten in ihrer Kasuistik von einer Patientin mit kritischer Hyperkalzämie bei primärem Hyperparathyreoidismus…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE
or Only Accept Required